Department of Medicine

Department of Medicine

  Division of General Internal Medicine

Division of General Internal Medicine Newsletter

  • GIM News
  • Donna L. Bishop, Editor
  • Next issue:
    October 2017
  • Submission deadline:
    September 29th, 2017
  • E-mail: Donna Bishop


Subject: Associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness – A PCRC Data Repository Expansion program
Principal Investigator: Yael Schenker, MD, MAS
Sponsor: Palliative Care Research Collaborative (PCRC) Group
Purpose of Grant: The objective of this project is to perform a secondary analysis of data obtained in a multisite randomized control trial of continuing versus discontinuing statins, in order to explore the relationship between polypharmacy, symptom burden, and quality of life in the setting of advanced, life-limiting illness.

Subject: Development of Educational Products for PDMP Systems User and Stakeholders
Principal Investigator: Walid Gellad, MD, MPH
Sponsor: PA Department of Health
Purpose of Grant: This project will develop educational materials for the Department of Health to use to educate physicians and other providers about how to optimally use the new Prescription Drug Monitoring Program.

Subject: STORM Implementation Program Evaluation
Principal Investigator: Walid Gellad, MD, MPH, and Leslie Hausmann, PhD
Sponsor: VA HSR&D
Purpose of Grant: Identifying patients at risk for adverse outcomes from prescription opioid therapy is an essential priority for VA. To address this need, the VA developed a Stratification Tool for Opioid Risk Management (STORM), a predictive model that estimates the risk of adverse outcomes among patients who were prescribed opioids. STORM is currently being implemented at VA facilities in a randomized fashion. This project, which is evaluating the rollout, is designed to provide insights for the VA on how best to design policies to improve quality and safety for Veterans and how best to implement STORM across facilities to reduce opioid-related adverse events and improve the safe treatment of pain.